Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2020-12-09
Target enrollment:
Participant gender:
Summary
This study aims to evaluate safety and efficacy of dimethyl fumarate treatment in patients
with primary progressive multiple sclerosis (PPMS).
Half of the patients will receive dimethyl fumarate and the other half will receive placebo.